Heart rate as a risk factor for atherosclerosis and cardiovascular mortality: The effect of antihypertensive drugs

Drugs

Volumn 57, Issue 5, 1999, Pages 713-724

  Palatini, Paolo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; IMIDAZOLINE I1 RECEPTOR; MIBEFRADIL; PHENYLALKYLAMINE;

ANTIHYPERTENSIVE THERAPY; ARTERY WALL; ATHEROSCLEROSIS; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; HEART FAILURE; HEART INFARCTION; HEART RATE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTENSION; METABOLISM; MONKEY; MORBIDITY; MORTALITY; REVIEW; RISK FACTOR; STRESS; SUDDEN DEATH; SYMPATHETIC TONE; TACHYCARDIA;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; HEART RATE; HUMANS; HYPERTENSION; RISK FACTORS;

EID: 0032927655     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199957050-00004     Document Type: Review

References (82)

1. Selby JV, Friedman GD, Quesenberry Jr CP. Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am J Epidemiol 1990; 131: 1017-27
2. Reed D, McGee D, Yano K. Biological and social correlates of blood pressure among Japanese men in Hawaii. Hypertension 1982; 4: 406-14
3. Garrison RJ, Kannel WB, Stokes J. Incidence and precursors of hypertension in young adults: the Framingham Offspring study. Prev Med 1987; 16: 235-51
4. Dyer AR, Persky V, Stamler J, et al. Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am J Epidemiol 1980; 112: 736-49
5. Gillum RF, Makuc DM, Feldman JJ. Pulse rate, coronary heart disease, and death: the NHANES I Epidemiologic Follow-up Study. Am Heart J 1991; 121: 172-7
6. Kannel WB, Wilson P, Blair SN. Epidemiologic assessment of the role of physical activity and fitness in development of cardiovascular disease. Am Heart J 1985; 109: 876-85
7. Palatini P, Julius S. Review article: 'heart rate and the cardiovascular risk'. J Hypertens 1997; 15: 3-17
8. Levy RL, White PD, Stroud WD, et al. Transient tachycardia: prognostic significance alone and in association with transient hypertension. JAMA 1945; 129: 585-8
9. Paffenbarger Jr RS, Thorne MC, Wing AL. Chronic disease in former college students - VIII: characteristics in youth predisposing to hypertension in later years. Am J Epidemiol 1968; 88: 25-32
10. Schroll M, Hagerup LM. Risk factors of myocardial infarction and death in men aged 50 at entry: a ten-year prospective study from the Glostrup population studies. Dan Med Bull 1977; 24: 252-5
11. Medalie JH, Kahn HA, Neufeld HN, et al. Five-year myocardial infarction incidence - II: association of single variables to age and birthplace. J Chronic Dis 1973; 26: 329-49
12. Kannel WB, Kannel C, Paffenbarger Jr RS, et al. Heart rate and cardiovascular mortality: the Framingham study. Am Heart J 1987; 113: 1489-94
13. Filipovsky J, Ducimeticre P, Safar ME. Prognostic significance of exercise blood pressure and heart rate in middle-aged men. Hypertension 1992; 20: 333-9
14. Sutton-Tyrrell K, Alcorn HG, Herzog H, et al. Morbidity, mortality, and antihypertensive treatment effects by extent of atherosclerosis in older adults with isolated systolic hypertension. Stroke 1995; 26: 1319-24
15. Palatini P, Casiglia E, Julius S, et al. Heart rate: a risk factor for cardiovascular mortality in elderly men. Arch Intern Med 1999; 159: 585-92
16. Aronow WS, Ahn C, Mercando AD, et al. Association of average heart rate on 24-hour ambulatory electrocardiograms with incidence of new coronary events at 48-month follow-up in 1,311 patients (mean age 81 years) with heart disease and sinus rhythm. Am J Cardiol 1996; 78: 1175-6
17. Gillman MW, Kannel WB, Belanger A, et al. Influence of heart rate on mortality among persons with hypertension: the Framingham study. Am Heart J 1993; 125: 1148-54
18. Norwegian Multicenter Study Group: timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981; 304: 801-7
19. Hjalmarson A, Gilpin EA, Kjekshus J, et al. Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol 1990; 65: 547-53
20. Disegni E, Goldbourt U, Reicher-Reiss H, et al. The predictive value of admission heart rate on mortality in patients with acute myocardial infarction. J Clin Epidemiol 1995; 48: 1197-205
21. Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results from an international trial of 41,021 patients. GUSTO-1 Investigators. Circulation 1995; 91: 1659-68
22. Maggioni AP, Zuanetti G, Mantini L, et al. The predictive value of pre-discharge heart rate on 8-month mortality in 7.831 patients with acute myocardial infarction in the fibrinolytic era [abstract]. Eur Heart J 1997; 18 (Abstr Suppl.): 352A
23. Perski A, Olsson G, Landou C, et al. Minimum heart rate and coronary atherosclerosis: independent relations to global severity and rate of progression of angiographic lesions in men with myocardial infarction at a young age. Am Heart J 1992; 123: 609-16
24. Palatini P, Julius S. Association of tachycardia with morbidity and mortality: pathophysiological considerations. J Hum Hypertens 1997; 11(1 Suppl.): S19-27
25. Julius S, Gudbrandsson T, Jamerson K, et al. Hypothesis. The hemodynamic link between insulin resistance and hypertension. J Hypertens 1991; 9: 983-6
26. Palatini P, Casiglia E, Pauletto P, et al. Relationship of tachycardia with high blood pressure and metabolic abnormalities: a study with mixture analysis in three populations. Hypertension 1997; 30: 1267-73
27. Kannel WB, Sorlie H. Hypertension in Framingham. In: Paul O, editor. Epidemiology and control of hypertension. New York; Stratton, 1975; 553-92
28. Stamler J, Berkson DM, Dyer A, et al. Relationship of multiple variables to blood pressure: findings from four Chicago epidemiologic studies. In: Paul O, editor. Epidemiology and control of hypertension. Miami: Symposia Specialists, 1975; 307-52
29. Cirillo M, Laurenzi M, Trevisan M, et al. Hematocrit, blood pressure, and hypertension. The Gubbio Population Study. Hypertension 1992; 20: 319-26
30. Stern MP, Morales PA, Haffner SM, et al. Hyperdynamic circulation and the insulin resistance syndrome ('Syndrome X'). Hypertension 1992; 20 (6): 802-8
31. Julius S, Pascual AV, London R. Role of parasympathetic inhibition in the hyperkinetic type of borderline hypertension. Circulation 1971; 44: 413-8
32. Deibert DC, DeFronzo RA. Epinephrine-induced insulin resistance in man. J Clin Invest 1980; 65: 717-21
33. Zeman RJ, Ludemann R, Easton TG, et al. Slow to fast alterations in skeletal muscle fibers caused by clenbuterol, a beta-2-receptor agonist. Am J Physiol 1988; 254: E726-32
34. Jamerson KA, Julius S, Gudbrandsson T, et al. Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension 1993; 21 (5): 618-23
35. Pollare T, Lithell H, Selinus I, et al. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988; 31: 415-20
36. Cohn JN. Relationship of plasma volume changes to resistance and capacitance vessel effects of sympathomimetic amines and angiotensin in man. Clin Sci 1966; 30: 267-78
37. Julius S, Pascual AV, Abbrecht P, et al. Effect of beta-adrenergic blockade on plasma volume in human subjects. Proc Soc Exp Biol Med 1972; 140: 982-5
38. Gordon D, Guyton J, Karnovsky N. Intimal alterations in rat aorta induced by stressfull stimuli. Lab Invest 1983; 45: 14-9
39. Palatini P. Exercise haemodynamics in the normotensive and the hypertensive subject. Clin Sci 1994; 87: 275-87
40. Mangoni AA, Mircoli L, Giannattasio C, et al. Heart rate-dependence of arterial distensibility in vivo. J Hypertens 1996; 14: 897-901
41. Bassiouny HS, Zarins CK, Kadowaki MH, et al. Hemodynamic stress and experimental aortoiliac atherosclerosis. J Vasc Surg 1994; 19: 426-34
42. Kaplan JR, Manuck SB, Clarkson TB. The influence of heart rate on coronary artery atherosclerosis. J Cardiovasc Pharmacol 1987; 10 Suppl. 2: S100-2
43. Beere PA, Glagov S, Zarins CK. Retarding effect of lowered heart rate on coronary atherosclerosis. Science 1984; 226: 180-2
44. Goldberg RJ, Larson M, Levy D. Factors associated with survival to 75 years of age in middle-aged men and women. The Framingham study. Arch Intern Med 1996; 156: 505-9
45. Julius S, Li Y, Brant D, et al. Neurogenic pressor episodes fail to cause hypertension, but do induce cardiac hypertrophy. Hypertension 1989; 13: 422-9
46. Palatini P, Maraglino G, Accurso V, et al. Impaired left ventricular filling in hypertensive left ventricular hypertrophy as a marker of the presence of an arrhytmogenic substrate. Br Heart J 1995; 73: 258-62
47. Palatini P, Visentin PA, Mormino P, et al. Left ventricular performance in the early stages of systemic hypertension. Am J Cardiol 1998; 81: 418-23
48. Julius S. Altered cardiac responsiveness and regulation in the normal cardiac output type of borderline hypertension. Circ Res 1975; 36 (6 Suppl. 1): 199-207
49. Persky V, Dyer AR, Leonas J, et al. Heart rate: a risk factor for cancer? Am J Epidemiol 1981; 114: 477-87
50. Erlebacher JA, Weiss JL, Eaton LW, et al. Late effects of acute infarct dilation on heart size: a two-dimensional echocardiographic study. Am J Cardiol 1982; 49: 1120-6
51. Coburn AF, Grey RM, Rivera SM. Observations on the relation of heart rate, life span, weight and mineralization in the digoxin-treated A/J mouse. Johns Hopkins Med J 1971; 128: 169-93
52. Schmidt-Nielsen K. Animal physiology: adaptation and environment. New York: Cambridge University Press, 1975: 133
53. Kaplan JR, Manuck SB, Adams MR, et al. Inhibition of coronary atherosclerosis by propranolol in behaviorally predisposed monkeys fed an atherogenic diet. Circulation 1987; 76: 1364-72
54. Lehtonen A. Effect of beta blockers on blood lipid profile. Am Heart J 1985; 109: 1192-8
55. Chobanian AV, Brecher P, Chan C. Effects of propranolol on atherogenesis in the cholesterol-fed rabbit. Circ Res 1986; 56: 755-62
56. Whittington-Coleman PJ, Carrier Jr O, Douglas BH. The effect of propranolol on cholesterol-induced atheromatous lesions. Atherosclerosis 1973; 18: 337-43
57. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic anti-arrhythmic drug therapy in acute myocardial infarction: an overview of results from randomized controlled trials. JAMA 1993; 270: 1589-95
58. Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 1986; 57: 43F-9F
59. The Goteborg Metoprolol Trial in acute myocardial infarction. Am J Cardiol 1984; 53: 10D-50D
60. The International Collaborative Study Group. Reduction of infarct size with the early use of timolol in acute myocardial infarction. N Engl J Med 1984; 310: 9-15
61. Taylor SH, Silke B, Ebbutt A, et al. A long-term prevention study with oxprenolol in coronary heart disease. N Engl J Med 1982; 307: 1293-301
62. Kjekshus JK. Comments on beta-blockers: heart rate reduction, a mechanism of action. Eur Heart J 1985; 6 (A Suppl.): 29-30
63. Eichorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart. Circulation 1996; 94: 2285-96
64. Packer M, Bristow MR, Cohn IN. The effect of Carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334 (21): 1349-55
65. MRC working party. Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J 1992; 304: 405-12
66. Collins R, Peto R, Mac Mahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990; 335: 827-38
67. Nul DR, Doval HC, Grancelli HO, et al. Heart rate is a marker of amiodarone mortality reduction in severe heart failure. The GESICA-GEMA Investigators. J Am Coll Cardiol 1997; 29: 1199-205
68. Stadler P, Leonardi L, Riesen W, et al. Cardiovascular effects of verapamil in essential hypertension. Clin Pharmacol Ther 1987; 42: 85-92
69. Kailasam MT, Parmer RJ, Cervenka JH, et al. Divergent effects of dihydropyridine and phenylalkylamine calcium channel antagonist classes on autonomic function in human hypertension. Hypertension 1995; 26: 143-9
70. Luscher TF, Clozel JP, Noll G. Pharmacology of the calcium antagonist mibefradil. J Hypertens 1997, 15 Suppl. 3; S11-8
71. Kung CF, Tschudi MR, Noll G, et al. Differential effects of the calcium antagonist mibefradil in epicardial and inframyocardial coronary arteries. J Cardiovasc Pharmacol 1995; 26: 312-8
72. Halperin AK, Icenogle MV, Kapsner CO, et al. A comparison of the effects of nifedipine and verapamil on exercise performance in patients with mild to moderate hypertension. Am J Hypertens 1993; 6: 1025-32
73. The Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction. The Danish Verapamil Infarction Trial II (DAVIT-II). Am J Cardiol 1990; 66: 779-85
74. Alderman MH, Cohen H, Rogué R, et al. Effect of long-acting and short-acting calcium antagonists on cardiovascular outcomes in hypertensive patients. Lancet 1997; 349: 594-8
75. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988; 319: 385-92
76. Hamada T, Watanabe M, Kaneda T, et al. Evaluation of changes in sympathetic nerve activity and heart rate in essential hypertensive patients induced by amlodipine and nifedipine. J Hypertens 1998; 16: 111-8
77. Clozel J, Ertel EA, Ertel SI. Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker. J Hypertens 1997; 15 Suppl. 5: S17-25
78. Van Zwieten PA. Centrally acting antihypertensives: a renaissance of interest. Mechanisms and haemodynamics. J Hypertens 1997; 15 Suppl. 1: S3-8
79. Ernsberger P, Koletsky RJ, Collins LA, et al. Sympathetic nervous system in salt-sensitive and obese hypertension: amelioration of multiple abnormalities by a central sympatholitic agent. Cardiovasc Drugs Ther 1996; 10: 275-82
80. Ernsberger P, Friedman JE, Koletsky RJ. The II-Imidazoline receptor: from binding site to therapeutic target in cardiovascular disease. J Hypertens 1997; 15 Suppl. 1: S9-23
81. Rosen P, Ohly P, Gleichmann H. Experimental benefit of moxonidine on glucose metabolism and insulin secretion in the fructose-fed rat. J Hypertens 1997; 15 Suppl. 1: S31-8
82. Ditullio NW, Cieslinski L, Matthews WD, et al. Mechanisms involved in the hyperglycemic response induced by clonidine and other alpha2-adrenoceptor agonists. J Pharmacol Exp Ther 1984; 228: 168-73